文献速递神经乳腺MR

MRI强化特征用于识别乳腺癌脑转移HER2过表达的表现

Performance of enhancement on brain MRI for identifying HER2 overexpression in breast cancer brain metastases.
PubMed 文献 · Eur J Radiol · 2021-09-11

本研究纳入38个经组织学证实的乳腺癌脑转移病灶,评估术前增强脑MRI的强化程度与HER2荧光原位杂交结果的关系。HER2阳性病灶的百分信号强度变化(PSIC)显著高于阴性病灶(310 vs 153,P=0.002),PSIC鉴别HER2过表达的AUC为0.88。在控制病灶大小、位置、分级、患者年龄、扫描仪场强和对比剂后,PSIC的准确度为92%、敏感度96%、特异度86%。结论认为MRI强化可能有助于识别HER2过表达,但需前瞻性验证。

要点

  • 乳腺癌脑转移灶的MRI强化程度(PSIC)在HER2阳性者中显著高于阴性者。
  • PSIC鉴别HER2过表达的AUC达0.88,多因素控制后准确度92%。
  • 该指标尚需前瞻性研究验证,目前不能替代病理检测。

关键影像表现/征象

  • HER2阳性乳腺癌脑转移灶的百分信号强度变化(PSIC)显著高于HER2阴性病灶(310 vs 153,P=0.002)。
  • PSIC鉴别HER2阳性与阴性病灶的AUC为0.88(P<0.001)。

诊断标准与关键数值

  • PSIC鉴别HER2过表达的AUC为0.88(P<0.001)。
  • 在控制病灶大小、位置、肿瘤分级、患者年龄、扫描仪磁场强度和对比剂的模型中,PSIC鉴别HER2阳性与阴性病灶的准确度为92%(35/38),敏感度为96%(23/24),特异度为86%(12/14)。

临床应用与阅片要点

  • 阅片时可关注乳腺癌脑转移灶的强化程度(PSIC),作为提示HER2状态的影像线索。
  • 该指标不能替代病理HER2检测,报告时应结合临床和病理结果。

局限性

  • 样本量小(38个病灶,29例患者),为单中心回顾性研究。
  • 结论需前瞻性研究验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

PURPOSE: To investigate whether enhancement on MRI could help identify HER2 overexpression in breast cancer brain metastases.

METHODS: We derived a cohort of 38 histologically proven breast cancer brain metastases with preoperative contrast-enhanced brain MRI and HER2 fluorescent in-situ hybridization of the resected/biopsied brain specimens from 2018 to 2021. Enhancement of the lesions was measured and compared using t-tests. Receiver operating characteristic and logistic regression analyses were performed to evaluate the performance of MRI enhancement in identifying HER2 overexpression.

RESULTS: The study cohort was comprised of 29 women with a mean age of 55 years (range: 31-81 years) with a total of 38 distinct lesions. The HER2-positive subcohort was comprised of 17 patients, while the HER2-negative subcohort was comprised of 13 patients. The percent signal intensity change (PSIC) of HER2-positive breast cancer brain metastases was significantly greater than that of HER2-negative lesions (310 v. 153, P = 0.002). The PSIC differentiated HER2-positive lesions from HER2-negative lesions with an area under the curve of 0.88 (P < 0.001). In a model controlling for lesion size, lesion location, tumor grade, patient age, scanner magnetic field strength, and contrast agent, the PSIC had an accuracy of 92% (35/38), sensitivity of 96% (23/24), and specificity of 86% (12/14) in differentiating HER2-positive lesions from HER2-negative lesions.

CONCLUSION: Enhancement on MRI may assist in identifying HER2 overexpression in breast cancer brain metastases, if validated prospectively.

来源:Eur J Radiol,查看原文。版权归原作者所有。

引用

  1. Young JR, Ressler JA, Mortimer JE, et al. Performance of enhancement on brain MRI for identifying HER2 overexpression in breast cancer brain metastases. Eur J Radiol. 2021. PMID: 34534735. doi:10.1016/j.ejrad.2021.109948

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。